



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, May 18, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Clinton Sheffield, MD
Bryan Larson, PharmD
Susan Siegfried, MD

Elizabeth Young, PharmD
Clayton Grace, RPh
Jake Jones, MD

Committee Members Excused:

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director
Andrea Rico, CPhT
Robyn Seely, PharmD

Bryan Larson, PharmD
Merelynn Berrett, RN
Alyssa Pitts, RN

University of Utah Drug Regimen Review Center Staff Present:

Elena Martinez Alonso, BPharm, Medical Writer

Other Individuals Present:

James McAdams, OPKO
Joanita Lake, U of U
Cody Ball, SelectHealth
Scott Clegg, Lilly
Jonathon Constance, U of U

Charissa Anne, Johnson & Johnson
Jeff Mussack, Otsuka
Joanne LaFleur, U of U
Xiaosi Liu, U of U

Meeting conducted by: Clinton Sheffield, MD

1. **Welcome & Housekeeping:** Clinton, Sheffield, MD opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of April Minutes:** Bryan Larson made a motion to approve the minutes from April with the deletion of duplicate line of text. Clinton Sheffield seconded the motion. Unanimous approval.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Vivitrol clinical PA criteria, excluding payment methods. The DUR Board also touched upon Selzentry, Entresto, and Movantik.
4. **Anti-Gout Agents- Allopurinol, Colchicine, Colchicine & Probenecid, Febuxostat, Lesinurad, Pegloticase:** Elena Martinez Alonso presented a review of Anti-Gout Agents with peer-reviewed research regarding the safety and

efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Public Comment:** N/A
6. **Other State Report:** Bryan Larson reported the PDL listings for agents in this class in other States' Medicaid programs.
7. **Committee Discussion:**
 - a. Clinton Sheffield stated that Allopurinol needs to be preferred indicating there is no inherent advantage to Febuxostat.
 - b. Elizabeth Young stated that despite the cost, colchicine does have a place for use depending on the patient and their needs.
 - c. Clinton Sheffield motioned that the treatments for gout are equally safe and efficacious for their approved indications recognizing the difference between acute and chronic management of gout. Elizabeth Young seconded the motion. Unanimous approval.
 - d. Clinton Sheffield motioned that not enough information is available pertaining to lesinurad's safety and efficacy for inclusion as preferred on the preferred drug list at this time. Elizabeth Young seconded. Unanimous approval.
8. **Public Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Bryan Larson seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** June 15, 2017 Parathyroid Hormone Analogs.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>